Semi-Annual Consolidated Statement Of Cash Flows

Noile-Immune Biotech Inc. - Filing #7270247

Concept As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-962,035,000 JPY
-1,127,594,000 JPY
Foreign exchange losses (gains)
JPY
440,000 JPY
Decrease (increase) in inventories
12,329,000 JPY
-16,975,000 JPY
Other, net
-7,684,000 JPY
-364,000 JPY
Subtotal
-992,836,000 JPY
-870,700,000 JPY
Interest and dividends received
475,000 JPY
43,000 JPY
Income taxes paid
-2,420,000 JPY
-2,420,000 JPY
Net cash provided by (used in) operating activities
-887,809,000 JPY
-873,076,000 JPY
Cash flows from investing activities
Net cash provided by (used in) investing activities
557,000 JPY
-5,316,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
JPY
2,508,040,000 JPY
Net cash provided by (used in) financing activities
2,500,000 JPY
1,913,086,000 JPY
Net increase (decrease) in cash and cash equivalents
-884,751,000 JPY
1,034,693,000 JPY
Cash and cash equivalents
4,670,939,000 JPY
5,555,691,000 JPY
4,520,997,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.